Clinical Trials Currently Recruiting Patients

  • Study: HALO-101 PEGPH20 in combination with KEYTRUDA® (pembrolizumab)
  • Indication: Non-Small Cell Lung Cancer and Gastric Cancer
  • Phase: Phase 1
  • More Information:

Notice

You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.

Ok